PMV PharmaceuticalsPMVP +3.48%34 Quick Ratio is 11.14 as of Mar. 2026, which is 50% below its 10-year median of 22.30. GuruFocus rates PMVP with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, PMV Pharmaceuticals ranks better than 80.82% on this metric.
PMV Pharmaceuticals has a quick ratio of 11.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for PMV Pharmaceuticals's Quick Ratio or its related term are showing as below:
PMVP'
s Quick Ratio Range Over the Past 10 Years
Min: 10.09 Med: 22.3 Max: 68.24
Current: 11.14
During the past 8 years, PMV Pharmaceuticals's highest Quick Ratio was 68.24. The lowest was 10.09. And the median was 22.30.
PMVP's Quick Ratio is ranked better than 80.82% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs PMVP: 11.14
PMV Pharmaceuticals (NAS:PMVP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
PMV Pharmaceuticals Quick Ratio Related Terms
PMV Pharmaceuticals Quick Ratio Historical Data
* Premium members only.
The historical data trend for PMV Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PMV Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PMV Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where PMV Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
PMV Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMV Pharmaceuticals (PMVP) has a Quick Ratio of 11.14 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PMV Pharmaceuticals and its competitors. This is 50% below median its historical median of 22.30. Over the past decade, PMV Pharmaceuticals' Quick Ratio has ranged from 10.09 to 68.24. According to the industry distribution chart, PMV Pharmaceuticals ranks #271 out of 1413 companies in the Biotechnology industry, placing it in the top 19.2%.
Is PMV Pharmaceuticals' Quick Ratio too high?
PMV Pharmaceuticals' current Quick Ratio of 11.14 is 50% below median its 10-year median of 22.30. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 68.24. The Biotechnology industry median Quick Ratio is 3.60. PMV Pharmaceuticals' value of 11.14 is 209.4% above this industry median. Based on the distribution chart, PMV Pharmaceuticals ranks #271 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PMV Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Quick Ratio compare to EDSA and IMA?
According to the Biotechnology industry distribution chart, PMV Pharmaceuticals ranks #271 out of 1413 companies for Quick Ratio. This places PMV Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. PMV Pharmaceuticals' value of 11.14 is 209.4% above this benchmark. Historically, PMV Pharmaceuticals' own Quick Ratio has ranged from 10.09 to 68.24 over the past decade. While the company's 10-year median is 22.30 vs. the industry median of 3.60, PMV Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PMV Pharmaceuticals's current Quick Ratio of 11.14 is 209.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on PMV Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PMV Pharmaceuticals's current Quick Ratio is 11.14, which is 50% below median its own 10-year median of 22.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Quick Ratio of 11.14. The current Quick Ratio is 11.14, which is 50% below median its 10-year median of 22.30 and 209.4% above the Biotechnology industry median of 3.60. PMV Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Quick Ratio is 11.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
34GF Score
Get the complete analysis for PMVP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMVP has been successfully added to your 
